These results emphasize that the unique mechanisms behind KRAS mutations in NSCLC and HRAS mutations in skin cancer are based on tissue-specific gene-regulatory elements rather than inherent differences in the functionality of the encoded proteins. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.